uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company develops AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia; and AMT-126, a gene therapy for the treatment of congestive heart failure and AMT-130 to treat huntington's disease. The company has collaboration and license agreements with Bristol-Myers Squibb Company, 4D Molecular Therapeutics, Synpromics. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone31-20-566-7394
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$11.28 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date4/29/2019 (Estimated)
OptionableOptionable
Uniqure (NASDAQ:QURE) Frequently Asked Questions
What is Uniqure's stock symbol?
Uniqure trades on the NASDAQ under the ticker symbol "QURE."
How were Uniqure's earnings last quarter?
Uniqure NV (NASDAQ:QURE) released its quarterly earnings data on Thursday, February, 28th. The biotechnology company reported ($0.59) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.67) by $0.08. Uniqure had a negative net margin of 738.25% and a negative return on equity of 47.73%. View Uniqure's Earnings History.
When is Uniqure's next earnings date?
What price target have analysts set for QURE?
10 Wall Street analysts have issued 1 year price objectives for Uniqure's shares. Their predictions range from $35.00 to $100.00. On average, they anticipate Uniqure's share price to reach $73.8750 in the next year. This suggests a possible upside of 16.5% from the stock's current price. View Analyst Price Targets for Uniqure.
What is the consensus analysts' recommendation for Uniqure?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Uniqure in the last year. There are currently 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Uniqure.
What are Wall Street analysts saying about Uniqure stock?
Here are some recent quotes from research analysts about Uniqure stock:
- 1. Cantor Fitzgerald analysts commented, ": We reiterate our OW rating and $81 PT on uniQure. This morning, Spark (Neutral) filed a 14D-9, which detailed a timeline (Figure 1) of potential partnership and acquisition talks the company had. Our key takeaway is that four parties, including Roche (RHHBY – NC) were in discussions regarding a co- development and co-promotion partnership relating to hemophilia A. Three of these parties (including Roche) were involved in acquisition talks. This detailed process indicates there is an immense interest in hemophilia gene therapy programs from pharma." (3/7/2019)
- 2. According to Zacks Investment Research, "UNIQURE B.V. is involved in developing gene therapy for patients of genetic or acquired diseases. It offers Glybera for the treatment of lipoprotein lipase deficiency, an orphan metabolic disease. The company's product pipeline includes which are in clinical trials are additional adeno-associated virus consist of AMT-060, AMT-021, AMT-110 and AAV2/glial. UNIQURE B.V. is headquartered in Amsterdam, the Netherlands. " (3/6/2019)
- 3. HC Wainwright analysts commented, "Our $73 price target, is based on a 13-year DCF analysis that incorporates rNPV of two clinical-stage pipeline products AMT-061 and AMT-130. For AMT-061, we assume a 70% POS driven by the compelling clinical updates and single- arm Phase 3 involving about 50 patients, along with RMAT and PRIME designations. We anticipate commercial launch during 2H21, with a NAB-based exclusion of 5%, and model risk-adjusted peak sales of roughly $765M, during 2028. We assume a launch price of $850K, which could be an underestimate based on the 7 plus years of anticipated durability." (2/26/2019)
- 4. Chardan Capital analysts commented, "We note organ-specific promoters will help mitigate toxicity issues associated with off-target expression of transgenes. In addition, better promoters means potentially lower dosage of vector genomes will be required to achieve therapeutic levels of therapeutic protein levels." (10/18/2018)
Has Uniqure been receiving favorable news coverage?
Headlines about QURE stock have been trending neutral on Sunday, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Uniqure earned a daily sentiment score of 0.2 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 3.0 out of 10, indicating that recent press coverage is unlikely to have an effect on the company's share price in the next several days.
Are investors shorting Uniqure?
Uniqure saw a decline in short interest in February. As of February 28th, there was short interest totalling 1,753,730 shares, a decline of 29.1% from the February 15th total of 2,473,269 shares. Based on an average daily trading volume, of 923,123 shares, the short-interest ratio is currently 1.9 days. Currently, 8.4% of the shares of the stock are short sold. View Uniqure's Current Options Chain.
Who are some of Uniqure's key competitors?
Some companies that are related to Uniqure include Alnylam Pharmaceuticals (ALNY), Sarepta Therapeutics (SRPT), Bausch Health Companies (BHC), Jazz Pharmaceuticals (JAZZ), Beigene (BGNE), SAGE Therapeutics (SAGE), Loxo Oncology (LOXO), Dr.Reddy's Laboratories (RDY), Perrigo (PRGO), Marina Biotech (MRNA), Catalent (CTLT), Amarin (AMRN), Nektar Therapeutics (NKTR), Alkermes (ALKS) and United Therapeutics (UTHR).
What other stocks do shareholders of Uniqure own?
Who are Uniqure's key executives?
Uniqure's management team includes the folowing people:
- Mr. Matthew Craig Kapusta, CEO, CFO & Exec. Director (Age 47)
- Dr. Sander Van Deventer M.D., Ph.D., Co-founder, Chief Scientific Officer & Gen. Mang. of Amsterdam (Age 65)
- Mr. Jonathan Garen, Chief Bus. Officer (Age 53)
- Prof. Hugo Katus, Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany
- Dr. Scott T. McMillan, Chief Operating Officer (Age 60)
Who are Uniqure's major shareholders?
Uniqure's stock is owned by many different of retail and institutional investors. Top institutional shareholders include FMR LLC (9.82%), 683 Capital Management LLC (2.91%), BlackRock Inc. (1.26%), RTW Investments LP (1.24%), Sphera Funds Management LTD. (0.62%) and Perceptive Advisors LLC (0.59%). Company insiders that own Uniqure stock include Alexander Edward Kuta III, Christian Klemt, David Schaffer, Deventer Sander Van, Harald Petry, Jeremy P Springhorn, Maria E Cantor, Matthew C Kapusta, Philip Astley-Sparke, Scott T Mcmillan and Steven Zelenkofske. View Institutional Ownership Trends for Uniqure.
Which institutional investors are selling Uniqure stock?
QURE stock was sold by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, WS Management Lllp, D. E. Shaw & Co. Inc., FMR LLC, BlackRock Inc., Squarepoint Ops LLC, Bellevue Group AG and Two Sigma Advisers LP. Company insiders that have sold Uniqure company stock in the last year include Alexander Edward Kuta III, Christian Klemt, David Schaffer, Deventer Sander Van, Jeremy P Springhorn, Matthew C Kapusta, Philip Astley-Sparke, Scott T Mcmillan and Steven Zelenkofske. View Insider Buying and Selling for Uniqure.
Which institutional investors are buying Uniqure stock?
QURE stock was acquired by a variety of institutional investors in the last quarter, including 683 Capital Management LLC, Alps Advisors Inc., Sphera Funds Management LTD., RTW Investments LP, Geode Capital Management LLC, Geode Capital Management LLC, Bank of America Corp DE and Caption Management LLC. View Insider Buying and Selling for Uniqure.
How do I buy shares of Uniqure?
Shares of QURE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Uniqure's stock price today?
One share of QURE stock can currently be purchased for approximately $63.43.
How big of a company is Uniqure?
Uniqure has a market capitalization of $2.39 billion and generates $11.28 million in revenue each year. The biotechnology company earns $-83,300,000.00 in net income (profit) each year or ($2.34) on an earnings per share basis.
What is Uniqure's official website?
How can I contact Uniqure?
Uniqure's mailing address is PAASHEUVELWEG 25A, AMSTERDAM P7, 1105 BP. The biotechnology company can be reached via phone at 31-20-566-7394 or via email at [email protected]
MarketBeat Community Rating for Uniqure (NASDAQ QURE)
MarketBeat's community ratings are surveys of what our community members think about Uniqure and other stocks. Vote "Outperform" if you believe QURE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe QURE will underperform the S&P 500 over the long term. You may vote once every thirty days.
